PharmaLinea, a private label supplement manufacturer, has been acquired by ANJAC Health & Beauty, a French industrial group that now comprises 17 companies in the fields of health, beauty, personal care, and food supplements.

ANJAC Health & Beauty is a French, family-owned industrial group specializing in the formulation, manufacturing, and filling of cosmetics, medical devices, drugs, and food supplements. The group now has 17 R&D sites and 24 manufacturing sites across Europe and North America.

PharmaLinea and its sister companies, the ingredient supplier Hermes Consilium and a production and manufacturing specialist called ErgoPharma, were each acquired as part of a full acquisition of Health Chain Group (HCG), to enable ANJAC to strengthen its health and pharma activities. The goal is to bridge food and supplementation to provide unique health solutions backed by clinical studies, the group reported. The acquisition also enhances ANJAC’s commercial presence in Central and Eastern Europe, Asia, the Middle East, and North America.

ANJAC was founded in 2008 and has a consolidated workforce of over 3,300 people, and a 2025 turnover of nearly €800 million projected, as an R&D and production partner for pharmaceutical labs, and beauty and wellness brands.

HCG is focused on the B2B nutraceutical space and is present in over 40 markets worldwide. Its structure is active across different industry segments, and its vertically-integrated model enables the group to control the entire value chain from ingredients to finished products.

ANJAC and PharmaLinea’s partnership will open new pathways for product innovation, scientific research, and comprehensive services for client brands. PharmaLinea will retain its distinctive identity, benefitting from ANJAC’s infrastructure, cross-sector expertise, and R&D resources.

“PharmaLinea and Health Chain Group was founded with a simple yet ambitious goal: to bring more science, integrity, and trust to the nutraceutical industry,” said Blaž Gorjup, chairman and founder of PharmaLinea. “Seeing that vision grow into a group recognized across the world fills me with pride and gratitude. Joining forces with ANJAC will allow HCG to reach even higher while staying true to its values. It’s because of this strong foundation and bright outlook that I chose to remain a minority shareholder and continue to be available to the company as it moves forward. My sincere thanks go to everyone who has contributed to this journey.”

“This marks an incredibly exciting new chapter for PharmaLinea. Becoming part of ANJAC Health & Beauty represents both a great milestone and a strong confirmation of how far we’ve come: the culmination of many years of hard work in establishing our company, our processes, our network, and our product pipeline,” said Anton Oražem, CEO of PharmaLinea. “We are truly proud to join such a renowned group that shares the same values, entrepreneurial DNA, and long-term vision for the future. With ANJAC’s extensive network across the health and beauty industries, PharmaLinea will gain access to new technologies, new innovation possibilities, and new partners, all of which will further strengthen our ability to deliver premium, clinically substantiated supplement solutions to our clients. This partnership opens an era of extraordinary opportunity. It will give wings to PharmaLinea’s story, while at the same time complementing and completing the offering that ANJAC provides to its partners worldwide. We are excited about the journey ahead and the value this collaboration will bring to both organizations.”

“We are delighted to welcome HCG to the ANJAC Group,” said Aurélien Chaufour, president of the ANJAC Group. “This partnership reflects our strong ambitions in the health and pharma segment, our strategy in clinically backed food and nutraceuticals solutions and the continued acceleration of our international growth. We share with HCG a common vision: delivering innovative, high-performance solutions with a premium level of service recognized by our clients.”